A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet.

Trial Profile

A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2010

At a glance

  • Drugs Aspirin; Aspirin/esomeprazole; Esomeprazole
  • Indications Cardiovascular disorders; Embolism and thrombosis; Fever; NSAID-induced gastrointestinal damage; Pain; Rheumatic disorders; Stroke
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Dec 2010 Actual initiation date changed from Oct 2009 to Sep 2009 as reported by ClinicalTrials.gov.
    • 30 Jun 2010 Actual end date changed from Oct 2009 to Dec 2009 as reported by ClinicalTrials.gov
    • 30 Jun 2010 Actual patient number (138) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top